Korro Bio (KRRO) Income from Continuing Operations (2018 - 2026)
Korro Bio (KRRO) posted Income from Continuing Operations of 19625000.0 for Q1 2026, down 121.12% on a QoQ basis from 92901000.0 in Q4 2025, and up 16.09% year-over-year from 16905590.45 in Q1 2025.
Korro Bio (KRRO) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Korro Bio's Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 19625000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 16.09% year-over-year to 19625000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 29445000.0 (up 852.88% YoY) and the FY2025 annual result came in at 25683000.0, up 31807.41% from the prior year.
- Income from Continuing Operations was 19625000.0 for Q1 2026 at Korro Bio, down from 92901000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 92901000.0 in Q4 2025 and bottomed at 25770000.0 in Q2 2025.
- A 5-year average of 7836882.35 and a median of 19605000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations tumbled 511.02% — and 2024, when it jumped 345.03%.
- Korro Bio's Income from Continuing Operations stood at 6186000.0 in 2022, then tumbled by 511.02% to 25426000.0 in 2023, then soared by 345.03% to 62301000.0 in 2024, then soared by 49.12% to 92901000.0 in 2025, then sank by 121.12% to 19625000.0 in 2026.
- Business Quant data shows KRRO's Income from Continuing Operations at 19625000.0 in Q1 2026, 92901000.0 in Q4 2025, and 18061000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.58 Bn | 466.79 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.80 Bn | 50.61 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Korro Bio | 122.37 Mn | 8.40 Mn | - | -19.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.63 Mn |
| Dec 31, 2025 | 92.90 Mn |
| Sep 30, 2025 | -18.06 Mn |
| Jun 30, 2025 | -25.77 Mn |
| Mar 31, 2025 | -23.39 Mn |
| Dec 31, 2024 | 62.30 Mn |
| Sep 30, 2024 | -21.00 Mn |
| Jun 30, 2024 | -21.83 Mn |
| Mar 31, 2024 | -19.56 Mn |
| Dec 31, 2023 | -25.43 Mn |
| Sep 30, 2023 | -18.49 Mn |
| Jun 30, 2023 | -17.65 Mn |
| Mar 31, 2023 | -19.61 Mn |
| Dec 31, 2022 | 6.19 Mn |
| Sep 30, 2022 | -19.55 Mn |
| Jun 30, 2022 | -21.29 Mn |
| Mar 31, 2022 | -23.39 Mn |
| Dec 31, 2021 | -21.50 Mn |
| Sep 30, 2021 | -25.16 Mn |
| Jun 30, 2021 | -17.66 Mn |